🧬 Does spine vs knee enthesis differ immunologically? Translational scRNAseq study: YES! Spine produces more IL-23 but shows attenuated IL-17 response vs knee #POS0084 #EULAR2026 @RheumNow https://t.co/itFrLEXSzZ

• https://x.com/Nellziade/status/2062550503393828865/photo/1

🔍 Are 2025 ASAS-SPARTAN criteria valid in early axSpA? SPACE cohort (n=669): HIGH specificity (97.5%) but LOWER sensitivity (60%) vs 2009 criteria (83%) #OP0239 #EULAR2026 @RheumNow https://t.co/9wNbtcbP0l

• https://x.com/Nellziade/status/2062546844421373976/photo/1

🎗️ Do targeted therapies raise cancer risk in SpA? French nationwide cohort (n=56,591): NO In fact, prolonged exposure REDUCES risk (wHR 0.86), especially haematological. #OP0238 #EULAR2026 @RheumNow https://t.co/dDveAmWpdX

• https://x.com/Nellziade/status/2062545816187699690/photo/1

💉 Does ivarmacitinib (selective #JAK1i work in nr-axSpA? Phase 3 RCT (n=304): ASAS40 39.7% vs 24.8% placebo at week 12 with sustained benefit at week 24 #OP0237 #EULAR2026 @RheumNow https://t.co/kofXnPp6qQ

• https://x.com/Nellziade/status/2062545287885787380/photo/1

💊 After TNFi failure in axSpA, switch to IL-17Ai or cycle TNFi? ROC-SpA (Phase 4 RCT, n=300): NO difference: ASAS40 15.2% vs 14.5% at week 24 #OP0235 #EULAR2026 @RheumNow https://t.co/45gisWiuoM

• https://x.com/Nellziade/status/2062544752814289277/photo/1

🔬 Can filgotinib improve axSpA? OLINGUITO (Phase 3 RCT, n=495): YES! ASAS40 39.5% vs 21% (r-axSpA) at week 16 #OP0234 #EULAR2026 @RheumNow https://t.co/0vj2KqSS1b

• https://x.com/Nellziade/status/2062544406004060651/photo/1

DESIR Cohort 10-year data (OP0102): SIJ structural lesions in #axSpA progress slowly, but prior MRI bone marrow oedema predicts later structural damage. bDMARD exposure was associated with less erosion progression supporting early biologic treatment Abstr OP0102 @RheumNow

Male sex independently associated with greater mSASSS increase (β 0.29), higher odds of ≥2-unit mSASSS progression (OR 2.08), and new syndesmophyte formation (OR 1.90) in #axSpA despite lower disease activity scores. Treat symptoms and progression Abstr OP0101 @RheumNow

RD in #IBD: 18.6% of 650 IBD pts affected, most commonly peripheral arthritis and AxSpa. Key finding: 14% of rheumatic manifestations preceded IBD diagnosis. Rheumatologists may see these pts first. GI-rheum collaboration is essential. @RheumNow #EULAR2026 POS0807 https://t.co/028yzOxJ2R

• https://x.com/JihaRheum/status/2062531819187085434/photo/1

Over 10 years in the GESPIC cohort, males with #axSpA had lower ASDAS/BASDAI and enthesitis but double the odds of significant spinal radiographic progression vs females (OR 2.08). Symptoms don’t always correlate to structural damage Abstr OP0101 @RheumNow #EULAR2026

After TNFi secondary failure: does MOA switch beat TNFi cycling? UK RWD (n=155): yes for #PsA (76% vs 57% drug survival at 12m) and axSpA (80% vs 68%), but not RA. Yet 74% of axSpA pts still got another TNFi. Evidence vs practice gap in plain sight. @RheumNow #EULAR2026 POS0776

Real-world bimekizumab in SpA/#PsA (BIMPACT, n=223): 76% retention at 12mo, even with 54% having prior IL-17i exposure. Effective after IL-17Ai failure. Oral candidiasis higher in PsA (16.5%) vs SpA (3.3%); led to discontinuation in ~25%. @RheumNow #EULAR2026 POS0798/POS0810

What defines MRI indicative of axSpA? This systematic lit review show adapting more stringent cutoffs in BME (>=4 SIJ quads, erosion >=3 quads, fat >=5 SIJ quads) & combined BME + structural lesions inc specificity. Time for updated definitions? AbsPOS0866 @RheumNow #EULAR2026 https://t.co/gkVbcOAiD3

• https://x.com/RHEUMarampa/status/2062515092722208958/photo/1

#OP0241 FASTLANE phase 4 trial showed TOFA was superior to PBO in early active axSpA, achieving significantly higher ASDAS inactive disease rates at 16 weeks (26.4% vs 7.4%) on background of naproxen. MRI osteitis improvement numerically favoured TOFA. #EULAR2026 @RheumNow https://t.co/dGETjkmfrh

• https://x.com/DrMiniDey/status/2062485261921964380/photo/1